Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) widened fourth quarter losses to 7 cents per share from 3 cents per share in the year ago period but with the recent approval of Northera, Wedbush expects the company to be an attractive acquisition target. Shares of the pharmaceutical climbed 73 cents to close at $5.95.
Chelsea An Attractive Take-Over Target
March 13, 2014 at 19:24 PM EDT
